title: Delayed Hemolysis After Parenteral Artesunate Therapy for Severe Malaria in Two Returning Canadian Travelers.
abstract: Delayed hemolysis after parenteral artesunate has been described in Europe and Asia, but until recently had not been reported in patients receiving the artesunate product used in the United States and Canada. We report two cases of severe delayed hemolysis after the treatment with intravenous artesunate in Canada.
authors.affiliation: Department of Medical Microbiology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Hematology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Infectious Diseases, University of Alberta, Alberta, Canada.
authors.forename: Marthe
authors.initials: M
authors.lastname: Charles
authors.affiliation: Department of Medical Microbiology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Hematology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Infectious Diseases, University of Alberta, Alberta, Canada.
authors.forename: Jeffery M
authors.initials: JM
authors.lastname: Patterson
authors.affiliation: Department of Medical Microbiology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Hematology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Infectious Diseases, University of Alberta, Alberta, Canada.
authors.forename: Leyla
authors.initials: L
authors.lastname: Asadi
authors.affiliation: Department of Medical Microbiology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Hematology, University of Alberta, Alberta, Canada; Department of Medicine, Division of Infectious Diseases, University of Alberta, Alberta, Canada shouston@ualberta.ca.
authors.forename: Stan
authors.initials: S
authors.lastname: Houston
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077332:Artesunate; D002163:Cameroon; D002170:Canada; D015023:Democratic Republic of the Congo; D006242:Haptoglobins / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014195:Travel
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D006242:Haptoglobins; D006454:Hemoglobins; D000077332:Artesunate; D007770:L-Lactate Dehydrogenase